nach oben

21.08.2023 | Research Article

Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study

verfasst von: Wolfgang Singer, Ann M. Schmeichel, David M. Sletten, Tonette L. Gehrking, Jade A. Gehrking, Jorge Trejo-Lopez, Mariana D. Suarez, Jennifer K. Anderson, Pamela H. Bass, Timothy G. Lesnick, Phillip A. Low

Erschienen in: Clinical Autonomic Research

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is a critical need for reliable diagnostic biomarkers as well as surrogate markers of disease progression in multiple system atrophy (MSA). Neurofilament light chain (NfL) has been reported to potentially meet those needs. We therefore sought to explore the value of NfL in plasma (NfL-p) in contrast to cerebrospinal fluid (NfL-c) as a diagnostic marker of MSA, and to assess NfL-p and NfL-c as markers of clinical disease progression.

Methods

Well-characterized patients with early MSA (n = 32), Parkinson’s disease (PD; n = 21), and matched controls (CON; n = 15) were enrolled in a prospective, longitudinal study of synucleinopathies with serial annual evaluations. NfL was measured using a high-sensitivity immunoassay, and findings were assessed by disease category and relationship with clinical measures of disease progression.

Results

Measurements of NfL-c were highly reproducible across immunoassay platforms (Pearson, r = 0.99), while correlation between NfL-c and -p was only moderate (r = 0.66). NfL was significantly higher in MSA compared with CON and PD; the separation was essentially perfect for NfL-c, but there was overlap, particularly with PD, for NfL-p. While clinical measures of disease severity progressively increased over time, NfL-c and -p remained at stable elevated levels within subjects across serial measurements. Neither change in NfL nor baseline NfL were significantly associated with changes in clinical markers of disease severity.

Conclusions

These findings confirm NfL-c as a faithful diagnostic marker of MSA, while NfL-p showed less robust diagnostic value. The significant NfL elevation in MSA was found to be remarkably stable over time and was not predictive of clinical disease progression.

Boeve BF, Silber MH, Ferman TJ et al (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16:622–630 PubMedCrossRef

Coon EA, Singer W (2020) Synucleinopathies. Continuum (Minneap Minn) 26(1):72–92 PubMed

Stankovic I, Fanciulli A, Sidoroff V, Wenning GK (2022) A review on the clinical diagnosis of multiple system atrophy. Cerebellum. https://doi.org/10.1007/s12311-022-01453-w CrossRefPubMed

Coon EA, Suarez MD, Ahlskog JE et al (2014) Survival in multiple system atrophy—insights from a large retrospective cohort. Ann Neurol 76:S39 ( abstract)

Low PA, Reich SG, Jankovic J et al (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14:710–719 PubMedPubMedCentralCrossRef

Wenning GK, Geser F, Krismer F et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12:264–274 PubMedPubMedCentralCrossRef

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt 4):861–870 PubMedCrossRef

Koga S, Aoki N, Uitti RJ et al (2015) When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 85:404–412 PubMedPubMedCentralCrossRef

Osaki Y, Wenning GK, Daniel SE et al (2002) Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology 59:1486–1491 PubMedCrossRef

10.

Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94:79–100 PubMedCrossRef

11.

Trojanowski JQ, Revesz T (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33:615–620 PubMedCrossRef

12.

Poggiolini I, Gupta V, Lawton M et al (2022) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145:584–595 PubMedCrossRef

13.

Rossi M, Candelise N, Baiardi S et al (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140:49–62 PubMedPubMedCentralCrossRef

14.

Shahnawaz M, Mukherjee A, Pritzkow S et al (2020) Discriminating alpha-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature 578:273–277 PubMedPubMedCentralCrossRef

15.

Singer W, Schmeichel AM, Shahnawaz M et al (2020) Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann Neurol 88:503–512 PubMedPubMedCentralCrossRef

16.

Martinez-Valbuena I, Visanji NP, Kim A et al (2022) Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy. Transl Neurodegener 11:7 PubMedPubMedCentralCrossRef

17.

Abdo WF, Bloem BR, Van Geel WJ et al (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol Aging 28:742–747 PubMedCrossRef

18.

Hall S, Ohrfelt A, Constantinescu R et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69:1445–1452 PubMedCrossRef

19.

Wang SY, Chen W, Xu W et al (2019) Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimers Dis 72:1353–1361 PubMedCrossRef

20.

Chelban V, Nikram E, Perez-Soriano A et al (2022) Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain 145:4398–4408 PubMedPubMedCentralCrossRef

21.

Zhang L, Cao B, Hou Y et al (2022) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Mov Disord 37:421–426 PubMedCrossRef

22.

Foubert-Samier A, Pavy-Le Traon A, Saulnier T et al (2022) An item response theory analysis of the unified multiple system atrophy rating scale. Parkinsonism Relat Disord 94:40–44 PubMedCrossRef

23.

Krismer F, Palma JA, Calandra-Buonaura G et al (2022) The unified multiple system atrophy rating scale: status, critique, and recommendations. Mov Disord 37:2336–2341 PubMedPubMedCentralCrossRef

24.

Palma JA, Vernetti PM, Perez MA et al (2021) Limitations of the unified multiple system atrophy rating scale as outcome measure for clinical trials and a roadmap for improvement. Clin Auton Res 31:157–164 PubMedPubMedCentralCrossRef

25.

Dreger M, Steinbach R, Gaur N et al (2021) Cerebrospinal fluid neurofilament light chain (NfL) predicts disease aggressiveness in amyotrophic lateral sclerosis: an application of the D50 disease progression model. Front Neurosci 15:651651 PubMedPubMedCentralCrossRef

26.

Mattsson N, Cullen NC, Andreasson U et al (2019) Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 76:791–799 PubMedPubMedCentralCrossRef

27.

Rojas JC, Wang P, Staffaroni AM et al (2021) Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology 96:e2296–e2312 PubMedPubMedCentralCrossRef

28.

Gilman S, Wenning GK, Low PA et al (2008) Second consensus conference on the diagnosis of multiple system atrophy. Neurology 71:670–676 PubMedPubMedCentralCrossRef

29.

Wenning GK, Tison F, Seppi K et al (2004) Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 19:1391–1402 PubMedCrossRef

30.

Low PA (1993) Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc 68:748–752 PubMedCrossRef

31.

Fealey RD, Low PA, Thomas JE (1989) Thermoregulatory sweating abnormalities in diabetes mellitus. Mayo Clin Proc 64:617–628 PubMedCrossRef

32.

Lipp A, Sandroni P, Ahlskog JE et al (2009) Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Arch Neurol 66:742–750 PubMedPubMedCentralCrossRef

33.

Wenning GK, Stankovic I, Vignatelli L et al (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 37:1131–1148 PubMedPubMedCentralCrossRef

34.

Singer W, Low PA (2015) Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study. Clin Auton Res 25:47–52 PubMedCentralCrossRef

35.

Bagnato S, Grimaldi LME, Di Raimondo G et al (2017) Prolonged cerebrospinal fluid neurofilament light chain increase in patients with post-traumatic disorders of consciousness. J Neurotrauma 34:2475–2479 PubMedCrossRef

36.

Varhaug KN, Torkildsen O, Myhr KM, Vedeler CA (2019) Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol 10:338 PubMedPubMedCentralCrossRef

37.

Singer W, Schmeichel AM, Shahnawaz M et al (2021) Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure. Ann Neurol 89:1212–1220 PubMedPubMedCentralCrossRef

38.

Kuhle J, Plavina T, Barro C et al (2020) Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler 26:1691–1699 PubMedCrossRef

39.

Palleis C, Morenas-Rodriguez E, Murcia FJM et al (2020) Longitudinal correlation between neurofilament light chain and UMSARS in multiple system atrophy. Clin Neurol Neurosurg 195:105924 PubMedCrossRef

40.

Song SK, Lee SK, Lee JJ et al (2011) Blood-brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy. Neurobiol Aging 32:2183–2189 PubMedCrossRef

41.

Amaador K, Wieske L, Koel-Simmelink MJA et al (2022) Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. J Neurol 269:3700–3705 PubMedPubMedCentralCrossRef

42.

Huehnchen P, Schinke C, Bangemann N et al (2022) Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 7:e154395 PubMedPubMedCentralCrossRef

43.

Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930–937 PubMedPubMedCentralCrossRef

Titel: Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study
verfasst von: Wolfgang Singer
Ann M. Schmeichel
David M. Sletten
Tonette L. Gehrking
Jade A. Gehrking
Jorge Trejo-Lopez
Mariana D. Suarez
Jennifer K. Anderson
Pamela H. Bass
Timothy G. Lesnick
Phillip A. Low
Publikationsdatum: 21.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Autonomic Research
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI: https://doi.org/10.1007/s10286-023-00974-6

Neu in den Fachgebieten Neurologie und Psychiatrie

07.12.2023 | DGPPN 2023 | Kongressbericht | Nachrichten

In Kooperation mit:: Zeitschrift für Allgemeinmedizin, DEGAM

04.12.2023 | Demenz | Nachrichten

Springer Medizin

Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study

Abstract

Purpose

Methods

Results

Conclusions

Neu in den Fachgebieten Neurologie und Psychiatrie

Klimaangst: Kollektives Anliegen erreicht Psychotherapie

Lassen sich altersassoziierte Erkrankungen via Bluttest vorhersagen?

Schluckstörungen im Alter – erkennen Sie die Anzeichen?

Alzheimer-Diagnose bereits im MCI-Stadium

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu in den Fachgebieten Neurologie und Psychiatrie

Klimaangst: Kollektives Anliegen erreicht Psychotherapie

Lassen sich altersassoziierte Erkrankungen via Bluttest vorhersagen?

Schluckstörungen im Alter – erkennen Sie die Anzeichen?

Alzheimer-Diagnose bereits im MCI-Stadium